Business Context and Reporting Period
This Form 6-K filing by Innate Pharma S.A., a foreign private issuer, was submitted on June 13, 2025. The report serves to distribute a press release dated June 13, 2025, to U.S. investors. The registrant files annual reports under Form 20-F.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a cover sheet referencing an external press release (Exhibit 99.1) and does not contain embedded financial tables or statements.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. No comparative financial data or operational updates are included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The content is limited to the filing header, exhibit index, and signature block.
Investor Verification Checklist
- Review the full text of the Press Release dated June 13, 2025 (Exhibit 99.1) referenced in this filing for specific operational or financial updates.
- Verify the company's latest audited financial statements in the most recent Form 20-F for baseline metrics.
- Confirm the identity of the signatory, Jonathan Dickinson, as the Chief Executive Officer.